Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 7851 - 7875 of 8033 in total
INGN 201(Advexin) is a replication-impaired adenoviral vector that carries the p53 gene, has been evaluated in both preclinical and clinical trials. Advexin is a well-tolerated and efficacious treatment for numerous cancers, both as monotherapy and in combination with radiation and/or chemotherapy agents.
Investigational
Investigational
Investigational
CGC-11047 is a polyamine analog designed to halt cell growth and induce apoptosis.
Investigational
Investigational
MYO-029 is a human anti-GDF-8 monoclonal antibody, which is being developed to treat muscle-wasting diseases including muscular dystrophy and age-related sarcopenia.
Investigational
Investigational
Investigational
Cambinol is a beta-naphtol derivative that inhibits NAD-dependant deacetylases to reduce cell survival under stress. This activity is currently being investigated for its use as a cancer treatment.
Experimental
XL418 is a novel anticancer compound.
Investigational
Ronacaleret is a calcium-sensing receptor antagonist.
Investigational
Experimental
Lactobacillus is a common bacteria found in the gut with Lactobacillus coryniformis K8 being originally isolated from artisan goat cheese.
Investigational
Investigational
Bimoclomol is an investigational drug that induces stress proteins and has cytoprotective effects.
Investigational
E-2012 is a gamma secretase modulator that is being evaluated as a potential new treatment for Alzheimer's disease.
Investigational
AP5280 is a novel N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-bound platinum (Pt) therapeutic designed to increase the therapeutic index relative to conventional, small-molecule platinum agents.
Investigational
Investigational
Investigational
Investigational
Investigational
Investigational
Investigational
Investigational
Investigational
Displaying drugs 7851 - 7875 of 8033 in total